secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001104659-24-112405
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Pharma appoints new CMO, CCO, CSO to accelerate growth
-------------------------------------------------------------

- Pierre Sayad appointed CMO, Terry Evans CCO, Christiana Cioffi CSO, effective Oct. 28, 2024.
- Sayad receives $450,000 base salary and 150,000 options; Evans $400,000 + 150,000 options.
- Cioffi receives $375,000 base salary and 150,000 options; each eligible for 40% target bonus.
- All three executives have extensive oncology and rare disease launch experience.
- Appointments aim to boost commercialization of PEDMARK for cisplatin-induced ototoxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/0001104659-24-112405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924112405/tm2427086d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-112405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer